Fryer Jacqueline F, Delwart Eric, Hecht Frederick M, Bernardin Flavien, Jones Morris S, Shah Nita, Baylis Sally A
Division of Virology, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Transfusion. 2007 Jun;47(6):1054-61. doi: 10.1111/j.1537-2995.2007.01235.x.
Plasma pools used in the manufacture of blood- and plasma-derived medicinal products are frequently contaminated with parvovirus B19. The presence of the novel human parvovirus PARV4 and a related variant PARV5 in manufacturing plasma pools was recently demonstrated. Another recently identified parvovirus, human bocavirus (HBoV), has been identified in respiratory samples from children with lower respiratory tract disease.
Recent and archived manufacturing plasma pools, as well as plasma from healthy blood donors (individual donations; pools of 16 donations) and febrile patients, were examined for the presence of PARV4 and PARV5 with conventional and TaqMan polymerase chain reaction assays. In addition, highly sensitive assays were used to examine the presence of HBoV DNA in manufacturing pools.
Of 351 recent manufacturing plasma pool samples, 14 (4%) tested positive for the presence of PARV4 and PARV5. This frequency was elevated in the archived pools. Viral loads ranged from less than 100 up to 4 million copies per mL plasma, with some pools containing a mixture of both viruses. In individual plasma samples from healthy blood donors and febrile patients, the frequencies of detection were 2 and 6 percent, respectively. No HBoV sequences were identified in manufacturing plasma pools (n = 167).
PARV4 and PARV5 are readily detected in manufacturing plasma pools, test pools (constructed from 16 donations), and individual donations derived from healthy blood donors. The prevalence of these viruses was increased in plasma samples from febrile patients. Despite the use of highly sensitive assays for HBoV, it was not possible to identify manufacturing plasma pools containing HBoV sequences.
用于生产血液和血浆衍生药品的血浆池经常被细小病毒B19污染。最近已证实在生产血浆池中存在新型人类细小病毒PARV4和相关变体PARV5。另一种最近发现的细小病毒，人博卡病毒（HBoV），已在患有下呼吸道疾病的儿童的呼吸道样本中被鉴定出来。
使用传统和TaqMan聚合酶链反应检测法，对近期和存档的生产血浆池，以及来自健康献血者（个体献血；16份献血的混合样本）和发热患者的血浆进行PARV4和PARV5检测。此外，还使用高灵敏度检测法检测生产血浆池中HBoV DNA的存在情况。
在351份近期生产血浆池样本中，14份（4%）检测出PARV4和PARV5呈阳性。在存档血浆池中，这一阳性率有所升高。病毒载量范围为每毫升血浆少于100份至400万份拷贝，一些血浆池同时含有两种病毒的混合物。在来自健康献血者和发热患者的个体血浆样本中，检测阳性率分别为2%和6%。在生产血浆池（n = 167）中未鉴定出HBoV序列。
在生产血浆池、检测池（由16份献血构建）以及来自健康献血者的个体献血中很容易检测到PARV4和PARV5。这些病毒在发热患者的血浆样本中的流行率有所增加。尽管使用了高灵敏度的HBoV检测方法，但仍无法鉴定出含有HBoV序列的生产血浆池。
